Research Topics
| Deenan PillaySummaryAffiliation: University College London Country: UK Publications
| Collaborators
|
Detail Information
Publications
Disease-associated XMRV sequences are consistent with laboratory contaminationStephane Hue
MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, UK
Retrovirology 7:111. 2010..Controversy has arisen from the failure of some studies to detect XMRV in PC or CFS patients and from inconsistent detection of XMRV in healthy controls...- The effect of intrinsic stochasticity on transmitted HIV drug resistance patternsAlison J Marks
Bradford University, UK
J Theor Biol 262:1-13. 2010..Stochastic models may therefore have an important role to play in interpreting differences in transmitted drug-resistance prevalence trends among epidemiological surveys... - Current patterns in the epidemiology of primary HIV drug resistance in North America and EuropeDeenan Pillay
Department of Virology, Windeyer Institute, Royal Free and University College Medical School, University College London, London, UK
Antivir Ther 9:695-702. 2004.... - The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapyDeenan Pillay
Centre for Virology, Division of Infection and Immunity, Royal Free and University College Medical School, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, UK
AIDS 20:21-8. 2006..Transmission of drug-resistant HIV-1 is well recognized. However, the impact of such transmission on natural history of infection remains unknown... - Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United KingdomDeenan Pillay
Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
J Infect Dis 192:967-73. 2005..Method 2 also nearly doubles estimates of numbers of individuals infected with multiclass drug-resistant virus. Our results identify an urgent need for new drugs within existing classes and new classes of antiretroviral therapy... - Multidrug resistant HIV and rapid progression of disease reported from New YorkDeenan Pillay
Centre for Virology, University College London, United Kingdom
Euro Surveill 10:E050224.2. 2005 - Antiretroviral resistance in the developing worldDeenan Pillay
Department of Virology, University College London, London, UK
J HIV Ther 12:95-6. 2007 - The priorities for antiviral drug resistance surveillance and researchDeenan Pillay
Department of Infection, University College London, London W1T 4JF, UK
J Antimicrob Chemother 60:i57-8. 2007..g. combination therapies) to limit emergence of resistance, and a focus on prevention strategies to prevent transmission... - Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo dataHuw Price
Chelsea and Westminster NHS Foundation Trust, London, UK
Antivir Ther 15:203-11. 2010..Here, we examined associations between the emergence of N348I and antiretroviral history in a large clinical database... - Virological response to initial antiretroviral regimens containing abacavir or tenofovirLoveleen Bansi
Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom
J Infect Dis 200:710-4. 2009..88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART... - Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapineRavindra K Gupta
Division of Infection and Immunity, University College London Medical School, London, United Kingdom
Pediatr Infect Dis J 29:e57-62. 2010..There are few medium-term virologic data in children from resource-limited settings taking adult fixed-dose-combination antiretroviral therapy (cART) without viral load monitoring... - Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
AIDS 22:349-56. 2008..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression... - Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapyAnna Maria Geretti
Royal Free Hampstead NHS Trust, Department of Virology, University College London Medical School, Health Protection Agency, London, England
Clin Infect Dis 48:1296-305. 2009..Studies to date, however, have described treatment outcomes predominantly in persons with subtype B infection or compared subtype B with diverse non-B subtypes grouped together... - Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitorsDavid Dunn
MRC Clinical Trials Unit, London, UK
Antivir Ther 13:771-7. 2008..These changes might be expected to affect the prevalence and patterns of protease resistance in the population of patients who experience treatment failure... - Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill
Research Department of Infection and Population Health, UCL Medical School, London, UK
J Clin Epidemiol 63:1101-9. 2010..To ascertain the degree of loss to follow-up in a cohort and to identify its predictors... - Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr
MRC Clinical Trials Unit, London, UK
J Antimicrob Chemother 65:129-37. 2010..The aim of this study was to evaluate which demographic factors and concomitant drugs are associated with lopinavir and atazanavir plasma concentration... - Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Lancet 370:1923-8. 2007..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure... - Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber
St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
Antivir Ther 16:805-14. 2011..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort... - Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assaysRavindra K Gupta
MRC Centre for Medical Molecular Virology, University College London, Windeyer Institute, London, UK
AIDS 24:1651-5. 2010..We wished to assess the contribution of full-length Gag to protease inhibitor susceptibility in viruses unexposed to protease inhibitors, in particular from the most common HIV-1 subtypes, namely subtype A and C... - Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individualsStephane Hue
UCL MRC Centre for Medical Molecular Virology, University College London, Windeyer Building, 46 Cleveland Street, London W1T 4JF, United Kingdom
J Virol 83:2645-54. 2009..These findings provide new insights for the planning and management of treatment programs in resource-rich and developing countries... - CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UKMark Bower
Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
Haematologica 94:875-80. 2009..Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma... - Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi
Research Department of Infection and Population Health, University College London Medical School, London, UK
J Acquir Immune Defic Syndr 52:391-6. 2009..However, the definition of an ALT flare is arbitrary and the extent to which such increases represent normal fluctuations has not been explored... - Late diagnosis in the HAART era: proposed common definitions and associations with mortalityCaroline A Sabin
Research Department of Infection and Population Health, UCL Medical School, London, UK
AIDS 24:723-7. 2010.... - Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapyChristos Mihailidis
Chelsea and Westminster Hospital NHS Trust, London, UK
AIDS 22:427-30. 2008..Furthermore, the presence of V118I as the sole nucleoside reverse transcriptase inhibitor mutation should not be over-interpreted when deciding on therapeutic options... - Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr
MRC Clinical Trials Unit, London, UK
Antivir Ther 13:675-85. 2008..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine... - Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1Robert J Gifford
Department of Infection, University College London, London, United Kingdom
J Virol 81:13050-6. 2007..The framework implemented here takes advantage of the vast amount of routinely generated HIV-1 sequence data and can provide epidemiological insights not readily obtainable through standard surveillance methods... - Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) StudyR J C Gilson
Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
HIV Med 11:152-60. 2010..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes... - The effect of transmitted HIV-1 drug resistance on pre-therapy viral loadLinda Harrison
HIV and Infections Group, MRC Clinical Trials Unit, London, UK
AIDS 24:1917-22. 2010..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus... - HIV-associated central nervous system diseases in the recent combination antiretroviral therapy eraLucy Garvey
Clinical Trials Centre, Winston Churchill Wing, St Mary s Hospital, London, W2 1NY, UK
Eur J Neurol 18:527-34. 2011..Data describing the incidence and survival of HIV-related central nervous system diseases (CNS-D) in recent years are sparse... - The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United KingdomHannah Green
HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
J Acquir Immune Defic Syndr 49:196-204. 2008..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable... - Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell countAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 21:1717-21. 2007..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART... - Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-scoreAlessandro Cozzi-Lepri
Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, London, United Kingdom
PLoS ONE 6:e25665. 2011.... - Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?Katherine J Lee
MRC Clinical Trials Unit, London, UK
Antivir Ther 12:949-56. 2007..To investigate transient increases in viral load during sustained suppression in children in the UK and Ireland Collaborative HIV Paediatric Study (CHIPS)... - A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trialHannah Green
MRC Clinical Trials Unit, London, UK
Antivir Ther 11:857-67. 2006..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure... - Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysisRavindra K Gupta
UCL MRC Centre for Medical Molecular Virology, University College London Medical School, London, UK
Lancet Infect Dis 9:409-17. 2009..This Review highlights the need for cheap point-of-care viral-load tests to identify early viral failures and limit the emergence of resistance... - Causes and consequences of incomplete HIV RNA suppression in clinical trialsAnton Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
HIV Clin Trials 10:289-98. 2009..However, other methods may improve precision and increase statistical power... - Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV SeroconvertersKrishnan Bhaskaran
Medical Research Council Clinical Trials Unit, London, UK
AIDS 18:1471-3. 2004..The virological and host determinants of this possible phenomenon are worth further exploration... - Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitorTristan J Barber
Medical Research Council Clinical Trials Unit, St Stephen s Centre, Chelsea and Westminster Hospital, 125 Kingsway, London, UK
J Antimicrob Chemother 67:995-1000. 2012..Scarce data exist from long-term cohorts on resistance incidence or mutational patterns emerging to different PIs... - The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domainsJean L Mbisa
Virus Reference Department, Microbiology Services, Colindale, Health Protection Agency, London, UK
Retrovirology 8:31. 2011..In this study we examined the genotypic, phenotypic and fitness correlates associated with the development of Q151M MDR in the absence of viral load monitoring... - Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UKJulie Fox
Department of HIV, Guys and St Thomas NHS Trust Kings College London, St Thomas Hospital, London, UK
AIDS 24:2397-401. 2010..To describe the frequency and risk factors of non-B HIV-1 subtypes in men who have sex with men (MSM) in the UK... - No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohortEleanor R Gray
Department of Infection and Immunity, University College London, London, United Kingdom
PLoS ONE 6:e18096. 2011..It has also been suggested that the virus can be found circulating amongst the general population. The discovery has been controversial, with conflicting results from attempts to reproduce the original studies... - Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trialsRavindra Gupta
Division of Infection and Immunity, University College London, London, United Kingdom
Clin Infect Dis 47:712-22. 2008..Resistance to antiretroviral combination therapy is associated with increased mortality. Understanding the relative risks of emerging resistance to first-line therapy is of importance for both resource-rich and resource-poor settings... - Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patientsCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Antivir Ther 8:301-8. 2003..New formulations of amprenavir, together with boosted regimens, may enhance the activity in the presence of protease inhibitor-resistant virus... - Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)Diana M Gibb
Medical Research Council Clinical Trials Unit, London, UK
Antivir Ther 7:293-303. 2002.... - Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitionsAlison E Brown
Centre for Infections, Health Protection Agency, University College London, London, UK
J Infect Dis 199:427-31. 2009..Previous analyses may have incorrectly assigned transmission events to the acutely HIV infected when they were more likely to have occurred during chronic infection... - Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversityRobert Gifford
Department of Infection, University College London, UK
AIDS 20:1521-9. 2006..However, it is not clear how reliable standard genotyping of these sequences is for describing HIV-1 genetic variation and for detecting novel genetic variants and epidemiological trends... - Hare TRIM5? restricts divergent retroviruses and exhibits significant sequence variation from closely related lagomorpha TRIM5 genesAdam J Fletcher
MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, Windeyer Building, London, United Kingdom
J Virol 84:12463-8. 2010..We propose that, like primates, lagomorphs have been subject to selective pressure from TRIM5-sensitive viruses, possibly related to the endogenous lentivirus RELIK found in both rabbits and hares... - Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late startersL Waters
Department of GU HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, UK
HIV Med 12:289-98. 2011..We investigated whether adverse responses to highly active antiretroviral therapy (HAART) associated with late HIV presentation are secondary to low CD4 cell count per se or other confounding factors... - UK HIV drug resistance database: background and recent outputsDavid Dunn
MRC Clinical Trials Unit, London, UK
J HIV Ther 12:97-8. 2007 - Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletionRavindra K Gupta
Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London, United Kingdom
PLoS Pathog 5:e1000443. 2009..This work suggests that tetherin binding agents might protect it from viral encoded countermeasures and thus make powerful antivirals... - Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation modelAndrew N Phillips
HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
Lancet 371:1443-51. 2008..Our aim was to study the potential consequences of such monitoring strategies, especially in terms of survival and resistance development... - The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin
Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
HIV Med 10:35-43. 2009.... - The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patientsAlan Winston
Department of Genitourinary/HIV Medicine, Chelsea and Westminster Hospital, London, UK
AIDS 16:2087-9. 2002..Both genetic routes may compromise abacavir and tenofovir activity... - Clinical epidemiology of HIV-associated end-stage renal failure in the UKLoveleen Bansi
University College London Medical School, London, UK
AIDS 23:2517-21. 2009..To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom... - Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestrationRavindra K Gupta
Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, United Kingdom
Proc Natl Acad Sci U S A 106:20889-94. 2009..Our observations emphasize the importance of tetherin in protecting mammals against viral infection and suggest that HIV-1 Vpu inhibitors may select active envelope mutants... - Clinical outcome in resistant HIV-2 infection treated with raltegravir and maravirocDarius Armstrong-James
Imperial College, St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
Antiviral Res 86:224-6. 2010..Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection... - HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United KingdomDaniella N Chilton
Medical Research Council Clinical Trials Unit, London, UK
Antivir Ther 15:985-91. 2010..We examined the characteristics of HIV-1 drug resistance in antiretroviral treatment (ART)-naive individuals migrating to the UK... - Management of paediatric HIV-1 resistanceRavindra K Gupta
University College London, Windeyer Building, UK
Curr Opin Infect Dis 22:256-63. 2009..Similarly, well resourced settings face challenges regarding extensive resistance accumulated over the past decade or more, particularly resulting from suboptimal therapies... - Determinants of HIV drug resistance mutations in plasma virus after treatment interruptionDaniella Chilton
Mortimer Market Centre, Camden Primary Care Trust, London, UK
AIDS 19:2174-5. 2005..We conclude that resistance testing is of value up to 3 months after treatment interruption, and may convey some benefit up to 12 months... - Transmission of HIV-1 drug resistanceJulian W Tang
Department of Virology, Windeyer Institute of Medical Sciences, Royal Free and University College Medical Schools, 46 Cleveland Street, London W1T 4JF, UK
J Clin Virol 30:1-10. 2004..As the use of HAART can only increase in the future, and compliance will always be a problem in such HAART-treated patients, baseline resistance testing should become a routine part of their management... - The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapyRuth Bridget Ferns
Division of Infection and Immunity, University College London, London, UK
AIDS 23:2159-64. 2009..To monitor HIV-1 integrase resistance mutations during raltegravir (RAL) therapy, including the impact of RAL interruption... - The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritisS Tariq Sadiq
Camden and Islington Community NHS Trust and Department of Sexually Transmitted Diseaeases and Virology, Royal Free and University College Medical School, University College, London, UK
AIDS 16:219-25. 2002..When BVL was poorly controlled by antiretroviral therapy, high SVL occurred during gonococcal urethritis, increasing the potential risk of transmitting both wild type and drug resistant strains of HIV-1... - Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1Adele L McCormick
Centre of Virology, Royal Free and University College London Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom
Antimicrob Agents Chemother 55:1806-9. 2011..Interestingly, the N348I and M184V double mutation compensated for the reduced NNRTI drug susceptibility observed in the N348I single mutant and marginally improved viral replicative capacity... - Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settingsAndrew N Phillips
Department of Infection and Population Health, UCL, UK
AIDS 25:843-50. 2011..There is concern that antiretroviral therapy (ART) use with only clinical monitoring for failure will result in high rates of transmission of virus with resistance to drugs currently in use... - Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conceptionSusie E Huntington
UCL Medical School, Royal Free Campus, UK
AIDS 25:1647-55. 2011.... - Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infectionSamir Dervisevic
Department of Virology, Royal Free and University College Medical School, 46 Cleveland Street, London W1T 4JF, UK
J HIV Ther 8:89-95. 2003.... - Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1Chris M Parry
UCL MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, UCL, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, United Kingdom
J Virol 83:9094-101. 2009..Thus, the amino terminus of Gag has a previously unidentified and important function in protease inhibitor susceptibility and replication capacity... - Update of the drug resistance mutations in HIV-1: Fall 2005Victoria A Johnson
Veterans Affairs Medical Center, Birmingham, AL, USA
Top HIV Med 13:125-31. 2005..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility... - Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000Paul Scott
PHLS Antiviral Susceptibility Reference Unit, Birmingham, UK
J Antimicrob Chemother 53:469-73. 2004..Our findings are relevant to the increased transmission of HIV drug resistance observed over this period... - Changes in the risk of death after HIV seroconversion compared with mortality in the general populationKrishnan Bhaskaran
MRC Clinical Trials Unit, 222 Euston Rd, London NW1 2DA, United Kingdom
JAMA 300:51-9. 2008..Mortality among human immunodeficiency virus (HIV)-infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population... - HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004Rana Chakraborty
Paediatric Infectious Diseases Unit, St George s Hospital, London
Pediatr Infect Dis J 27:457-9. 2008..Three-class resistance was noted in 42 samples (14.1%). Our study also highlighted underutilization of testing and the need for prompt genotyping after drug discontinuation which may have lead to an underestimation of HIV-1 resistance... - Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infectionsStephen Taylor
HPA Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, UK
Antivir Ther 8:479-83. 2003..We conclude that in the presence of suboptimal ART, sexually transmitted infections may enhance the spread of drug-resistant HIV-1... - Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutationsStephen Taylor
Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, Birmingham B9 5SS, UK
AIDS Res Hum Retroviruses 19:353-61. 2003..We provide "proof of principle" that such mutations can therefore become "fixed" within the circulating virus pool... - Resistance tests: what do clinical trials tell us?Nicola Price
J HIV Ther 7:80-6. 2002.... - Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006Florence Damond
APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
J Clin Microbiol 46:2088-91. 2008..Quantification varied between laboratories, and international standardization of quantification assays is strongly needed... - HIV phylogeneticsDeenan Pillay
BMJ 335:460-1. 2007 - HIV viral load: the myth of the undetectable?Deenan Pillay
PHLS Antiviral Susceptibility Reference Unit, Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
Rev Med Virol 12:391-6. 2002..I also consider other possible uses of HIV-1 quantification in clinical practice, such as identifying the inherent potency of antiviral regimens... - Analysis of HIV-1 variation in blood and semen during treatment and treatment interruptionBhudipa Choudhury
PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham, United Kingdom
J Med Virol 68:467-72. 2002..Once successful therapy had been recommenced, it was possible to distinguish distinct populations of virus in the two compartments. These data support the hypothesis that the male genital tract represents a distinct HIV-1 reservoir... - World Health Organization/HIVResNet Drug Resistance Laboratory StrategySilvia Bertagnolio
World Health Organization, HIV Department, Geneva, Switzerland
Antivir Ther 13:49-57. 2008..As of August 2007, assessment for accreditation has been conducted in 30 laboratories, covering the WHO's African, South-East Asia, Western Pacific, and the Caribbean Regions... - Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch
Harvard Medical School, Boston, Massachusetts, USA
Clin Infect Dis 47:266-85. 2008..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important... - Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trialDeenan Pillay
Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Birmingham Public Health Laboratory, Birmingham, United Kingdom
J Infect Dis 186:617-25. 2002..No differences were observed in the frequency of development of resistance mutations L90M (P=1.00) and D30N (P=.61) in B and non-B viruses. In conclusion, no evidence that subtype determined virologic response to therapy was found... - Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptaseAlan Winston
Department of GU and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
AIDS 18:949-51. 2004 - Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integraseRichard E Myers
Virus Reference Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW95EQ, United Kingdom
J Virol 82:9228-35. 2008..The validation of covariation as a predictive tool will be dependent on monitoring the evolution of HIV-1 integrase under drug selection pressure... - Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in womenInmaculada Jarrin
National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
Am J Epidemiol 168:532-40. 2008..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women... - Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyPatricia Cane
BMJ 331:1368. 2005..CONCLUSIONS: The United Kingdom has one of the highest reported rates of primary resistance to HIV drugs worldwide. Prevalence seems still to be increasing and is high in all demographic subgroups... - Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003Bernard Masquelier
Departement de Virologie et Immunologie biologique, CHU Bordeaux, France
J Acquir Immune Defic Syndr 40:505-11. 2005..To examine factors influencing the rate of transmitted drug resistance (TDR) among seroconverters, with particular emphasis on 3 widely used genotypic drug resistance algorithms... - Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck
Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
Antimicrob Agents Chemother 50:694-701. 2006..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype... - Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA loadDaniela Bezemer
Municipal Health Service Amsterdam, The Netherlands
Antivir Ther 11:173-8. 2006..043). No difference in HIV-1 RNA load was observed. These results, together with the apparent pressure to mutate at the resistance-associated positions exemplify the decreased fitness of viruses carrying 21 5Y/F, 70R or 184V... - Update of the Drug Resistance Mutations in HIV-1: 2005Victoria A Johnson
Veterans Affairs Medial Center, Birmingham, AL, USA
Top HIV Med 13:51-7. 2005..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility... - Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationRami Kantor
Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
PLoS Med 2:e112. 2005..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate... - Update of the drug resistance mutations in HIV-1: Fall 2006Victoria A Johnson
Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
Top HIV Med 14:125-30. 2006..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility... - HIV resistance and the developing worldRavindra Kumar Gupta
Department of Infectious Diseases, John Radcliffe Hospital, Oxford, UK
Int J Antimicrob Agents 29:510-7. 2007.... - HIV-1 protease and reverse transcriptase mutations for drug resistance surveillanceRobert W Shafer
Division of Infectious Diseases, Stanford University, Stanford, California, USA
AIDS 21:215-23. 2007..However, such programs will not produce comparable estimates unless a standardized list of drug-resistance mutations is used to define transmitted resistance... - Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips
AIDS 19:487-94. 2005..3195% CI 0.15-0.61; p = 0.0008). CONCLUSION: In routine practice, rates of viral load failure and of resistance detection in patients who started ART with three or four drugs are appreciable... - Long-term persistence of primary genotypic resistance after HIV-1 seroconversionDavid Pao
Royal Sussex County Hospital, Brighton, United Kingdom
J Acquir Immune Defic Syndr 37:1570-3. 2004.... - Update of the drug resistance mutations in HIV-1: 2004Victoria A Johnson
Veterans Affairs Medical Center, Birmingham, AL, USA
Top HIV Med 12:119-24. 2004 - Update of the drug resistance mutations in HIV-1: 2007Victoria A Johnson
Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
Top HIV Med 15:119-25. 2007